Indications and uses
• temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • menstrual cramps • headache • toothache • the common cold • temporarily reduces fever
• temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • menstrual cramps • headache • toothache • the common cold • temporarily reduces fever
• do not take more than directed • the smallest effective dose should be used • drink a full glass of water with each dose • if taken with food, this product may take longer to work adults and children 12 years and older: • take 1 capsule every 8 to 12 hours while symptoms last • for the first dose you may take 2 capsules within the first hour • do not exceed 2 capsules in any 8- to 12-hour period • do not exceed ...
• each capsule contains: sodium 20 mg • store at 20-25°C (68-77°F) avoid high humidity and excessive heat above 40°C (104°F) • do not use if printed foil under cap is broken or missing • read all directions and warnings before use. Keep carton.
Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)*
*nonsteroidal anti-inflammatory drug
Pain reliever/fever reducer
Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
ask a health professional before use. It is especially important not to use naproxen sodium during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
adults and children 12 years and older: |
|
children under 12 years: |
|
FD&C blue #1, gelatin, glycerin, lactic acid, mannitol, pharmaceutical ink, polyethylene glycol, povidone, propylene glycol, purified water, sorbitan, sorbitol
Call 1-800-910-6874
naproxen sodium capsules, 220 mg (NSAID)
pain reliever/fever reducer
Compare to the active ingredient of Aleve® Liquid Gels
strength to last 12 hours
ACTUAL SIZE
# LIQUID GELS** {Replace "#" with the number of liquidgels in the product}
(**LIQUID-FILLED CAPSULES)

| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| NAPROXEN SODIUM | ACTIVE INGREDIENT | 9TN87S3A3C | 2 | |
| NAPROXEN | ACTIVE MOIETY | 57Y76R9ATQ | 2 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 2 | |
| GELATIN | INACTIVE INGREDIENT | 2G86QN327L | 2 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| LACTIC ACID | INACTIVE INGREDIENT | 33X04XA5AT | 2 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 2 | |
| POLYETHYLENE GLYCOLS | INACTIVE INGREDIENT | 3WJQ0SDW1A | 2 | |
| POVIDONES | INACTIVE INGREDIENT | FZ989GH94E | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| SORBITAN | INACTIVE INGREDIENT | 6O92ICV9RU | 2 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 11673-742 | 11673-742-27, 11673-742-06, 11673-742-58 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NAPROXEN SODIUM | 9TN87S3A3C | ACTIB |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
| GELATIN | 2G86QN327L | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| LACTIC ACID | 33X04XA5AT | IACT |
| MANNITOL | 3OWL53L36A | IACT |
| POLYETHYLENE GLYCOL | 3WJQ0SDW1A | IACT |
| POVIDONE | FZ989GH94E | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
| SORBITAN | 6O92ICV9RU | IACT |
| SORBITOL | 506T60A25R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | PASTE, DENTIFRICE / DENTAL | NA | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | CREAM / TOPICAL | 1 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / DENTAL | 2 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRALESIONAL | 45 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 113 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / ORAL | 27120 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / TOPICAL | 0.75 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE / ORAL | 26.3 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET / SUBLINGUAL | 6 mg | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, DELAYED RELEASE / ORAL | 1791 mg | ||
| GELATIN | GELATIN | 2G86QN327L | WAFER / ORAL | NA | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, COATED PELLETS / ORAL | 65 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | CAPSULE / ORAL | 300 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SUSPENSION / ORAL | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / RECTAL | 3315 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SUSPENSION / ORAL | 45000 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FOR SUSPENSION / ORAL | 7621 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | OINTMENT / TOPICAL | 10 %w/w | ||
| GELATIN | GELATIN | 2G86QN327L | GUM, CHEWING / BUCCAL | 102 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | LIQUID / ORAL | 53460 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1.04 %w/v | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, EXTENDED RELEASE / ORAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| POVIDONES | POVIDONE | FZ989GH94E | SUSPENSION / AURICULAR (OTIC) | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | ELIXIR / ORAL | 9306 mg | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET / ORAL | 46 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, CONCENTRATE / INTRAVENOUS | 220 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, ORALLY DISINTEGRATING / ORAL | 15.03 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | LIQUID / ORAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SHAMPOO / TOPICAL | 0.75 %w/w | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, CHEWABLE / ORAL | 48 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | DOUCHE / VAGINAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / RECTAL | 27 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / VAGINAL | 750 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | GUM, CHEWING / ORAL | 6168 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GEL / OPHTHALMIC | 25 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / SUBLINGUAL | 495 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SYSTEM / TOPICAL | 6300 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT, AUGMENTED / TOPICAL | 714 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER, FOR SOLUTION / ORAL | 3767 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION, SUSPENSION / INTRAMUSCULAR | 1.3 mg | ||
| GELATIN | GELATIN | 2G86QN327L | PASTE / DENTAL | 252 mg | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET, DELAYED RELEASE / ORAL | 19 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CREAM / TOPICAL | 36.8 %w/w | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | CREAM / VAGINAL | 0.81 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | POWDER, FOR SUSPENSION / ORAL | 12000 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CONCENTRATE / ORAL | 600 mg/1ml | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET, SUGAR COATED / ORAL | NA | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION, CONCENTRATE / ORAL | 300 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021920-001 | NAPROXEN SODIUM | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 |
| N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 |
| N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 |
| N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 |
| N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 |
| N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 |
| N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | |
| N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N021920-001 | NAPROXEN SODIUM | EQ 200MG BASE | CAPSULE / ORAL | RLD, RS | 2006-02-17 | f41ea6bd6efb… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 10022344 | 2026-03-03 | U-1731 | Drug product | 2018-07-23 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 10022344 | 2026-03-03 | U-1732 | Drug product | 2018-07-23 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 10028925 | 2026-03-03 | U-1731 | Drug product | 2018-07-24 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 10028925 | 2026-03-03 | U-1732 | Drug product | 2018-07-24 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 11090280 | 2026-03-03 | U-1731 | Drug product | 2021-08-24 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 11090280 | 2026-03-03 | U-1732 | Drug product | 2021-08-24 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 9693978 | 2026-03-03 | Drug product | 2017-11-13 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021920-001 | 9693979 | 2026-03-03 | Drug product | 2017-11-13 | 6a471c1ec25d… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| fcd4b0bc-1705-4fc2-8c4b-7fd4cc8948ff | ba87f049-0bac-47fa-adb8-cbce089e407d | 2020-12-18 | Warnings | ba87f049-0bac-47fa-adb8-cbce089e407d |
Adverse event summaries are temporarily unavailable. Other product information remains available.